Novel mental retardation–epilepsy syndrome linked to Xp21.1–p11.4 by Hedera, Peter et al.
Novel Mental Retardation–Epilepsy
Syndrome Linked to Xp21.1–p11.4
Peter Hedera, MD,1 David Alvarado, BS,1 Ahmad Beydoun, MD,1 and John K. Fink, MD1,2
We evaluated a kindred with X-linked mental retardation and epilepsy. Seven affected males with mild to moderate
mental retardation developed seizures (primarily generalized, tonic–clonic, and atonic) that began on average at 6.8
months of age (range, 4 to 14 months). These patients did not have a history of infantile spasms. There were no
dysmorphic features. Other than mental retardation, the neurological examination was unremarkable, with exception of
2 affected subjects who had mild generalized rigidity and ataxia. We identified tight linkage to a group of markers on
Xp21.1–p11.4. A maximum two-point LOD score of 3.83 at   0 was obtained for markers DXS8090, DXS1069,
DXS8102, and DXS8085. This locus spans 7.7cM between DXS1049 and DXS8054 and does not overlap the locus for
X-linked West syndrome. The tetraspanin gene, implicated in nonspecific mental retardation, is mapped to this region.
We sequenced the tetraspanin coding sequence in subjects with X-linked mental retardation and epilepsy and did not
identify disease-specific mutations. The syndrome we describe, designated X-linked mental retardation and epilepsy, is
clinically and genetically distinct from X-linked West syndrome and other X-linked mental retardation–epilepsy syn-
dromes.
Ann Neurol 2002;51:45–50
Mental retardation (MR) is a common disorder that
affects males with disproportionate frequency. It is es-
timated that X-linked inheritance is responsible for
25% of all MR.1 X-linked mental retardation (XLMR)
is clinically heterogeneous. XLMR is classified as non-
specific when reduced intelligence quotient (IQ) is the
only clinical abnormality, and as syndromic when rec-
ognizable metabolic abnormalities, neurological defi-
cits, or dysmorphic features are present. A total of 202
XLMR conditions have been genetically mapped, and
33 XLMR genes have been identified.2
Seizures are features of several XLMR disorders. The
combination of seizures and mental retardation some-
times represents metabolic abnormalities or develop-
mental abnormalities of brain formation.3–7 At other
times, however, epilepsy and XLMR can occur without
diagnostic laboratory or neuroimaging abnormalities.
West syndrome characterized by MR, a type of myo-
clonic seizure known as infantile spasm (IS), and a
unique encephalographic pattern (hypsarrhythmia), is
usually sporadic or secondary to underlying brain dis-
turbance, such as tuberous sclerosis.8 However, in sev-
eral families, West syndrome has been transmitted as
an X-linked disorder (OMIM # 308350) and has been
mapped to a 7-cM locus on Xp21.3–Xp22.1.9,10
We evaluated a kindred in which epilepsy and MR
were found to be transmitted as an X-linked recessive
trait. We designate this condition X-linked mental re-
tardation–epilepsy syndrome (XMRE). Seizure pattern
and degree of mental retardation distinguish this syn-
drome from West syndrome. We performed genetic
linkage analysis and identified a tight linkage between
XMRE and polymorphic microsatellite markers span-
ning a 7.7-cM locus on Xp21.1–p11.4 that does not
overlap the West syndrome locus on Xp21.3–22.1.10
Tetraspanin (TM4SF2), a recently identified gene
that causes MR, was mapped to Xp11.4.11 We se-
quenced the TM4SF2 coding region and found no
mutations in affected subjects from our XMRE kin-
dred. This finding indicates that TM4SF2 coding se-
quence mutations do not cause Xp21.3–22.1-linked
XMRE.
Patients and Methods
Clinical, and Laboratory Studies
We evaluated 20 members of a nonconsanguinous North
American kindred of Polish descent (Fig 1). Informed con-
sent was obtained from each subject as specified by the Uni-
versity of Michigan Institutional Review Board. Subjects
were diagnosed as affected or unaffected with MR and epi-
lepsy on the basis of history and neurological examination
and of review of the medical records at the time of blood
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collection and before genotyping. Information about age of
seizure onset and seizure semiology was obtained by inter-
viewing the parents of affected subjects and reviewing med-
ical records. Electroencephalographic (EEG) tracings were
examined for subjects IV-1 and IV-5; EEG reports were re-
viewed for subjects IV-6 and IV-8. Electromyography
(EMG) and nerve conduction studies were performed on
subjects IV-5 and IV-9; magnetic resonance imaging (MRI)
of the brain were performed on subjects IV-1, IV-5, IV-8,
IV-9, and IV-17; fragile X analysis was performed on sub-
jects IV-1, IV-5, IV-9, IV-17, and IV-18; and urine meta-
bolic screen, venous lactate and pyruvate, and plasma very-
long-chain fatty acid analysis obtained on subjects IV-1,
IV-5, IV-9, and IV-17. High-resolution prometaphase karyo-
type was obtained for subject IV-5. Formal psychometric as-
sessment was obtained for subjects IV-1, IV-5, IV-9, and
IV-18.
Genetic Linkage Analysis
Pedigree analysis (see Fig 1) was consistent with transmission
of the disorder as a monogenic X-linked recessive trait.
Therefore, we analyzed 37 microsatellite polymorphisms
spaced 5 to 20 20cM throughout the X-chromosome for
linkage with the disorder. Microsatellite DNA polymor-
phisms were analyzed as previously described.12
We performed genetic linkage analysis using the unaf-
fected grandfather (subject II-1, Fig 1), his 8 daughters (sub-
jects III-1 through III-8), 5 of whom were considered obli-
gate maternal carriers (subjects III-1, III-3, III-4, III-5, and
III-8); 7 living affected subjects (subjects IV-1, IV-5, IV-6,
IV-8, IV-9, IV-17, and IV-18), and 5 living unaffected sub-
jects (IV-2, IV-3, IV-13, IV-14, and IV-15). Two-point
linkage analyses were performed with the MLINK subrou-
tine of the LINKAGE program, using an X-linked model of
disease inheritance and disease allele frequency of 0.001. We
assigned genetic penetrance of 0.90 for lod-score calculations.
Lod scores were calculated with marker allele frequencies as-
sumed to be equal because the small family size prevented
accurate estimation of marker allele frequency within this
family.
Analysis of the Tetraspanin Gene
Intronic primers were designed for seven TM4SF2 exons
based on the published TM4SF2 DNA sequence (www3.
ncbi.nlm.nih.gov) using Lasergene software. TM4SF2 exons
were amplified from gDNA samples of all affected and unaf-
Fig 1. X-linked mental retardation–epilepsy (XMRE) pedigree.
46 Annals of Neurology Vol 51 No 1 January 2002
fected subjects. Polymerase chain reaction (PCR) products
were purified through sephadex G-50 columns and sequenced
using the ABI PRISM dRhodamine Terminator Cycle Se-
quencing Ready Reaction and the ABI PRISM 3100 Genetic
Analyzer (PE Applied Biosystems, Foster City, CA). Each
exon was sequenced in both directions and DNA sequence
analyzed using SeqMan software (DNA Star, Boston, MA).
Results
Clinical Features of X-Linked Mental Retardation,
Epilepsy Syndrome
PEDIGREE ANALYSIS AND EXAMINATION OF UNAFFECTED
SUBJECTS. The 72-year-old grandfather (subject II-1;
see Fig 1) and his 8 daughters, including obligate car-
riers (subjects III-1, III-3, III-4, III-5, and III-8; see
Fig 1), had a normal neurological examination and no
history of seizures, developmental delay, or learning
disabilities. The lowest education level achieved was
high school completion. The patient’s wife (subject
II-2) reportedly had normal intelligence and no history
of seizures. She died at age 55 years from an unspeci-
fied cardiac cause. A review of the extended family on
her side did not show any history of seizures or MR.
Obligate maternal carriers (subjects III-1, III-3,
III-4, III-5, and III-8; see Fig 1) had 7 affected sons, 5
unaffected daughters (IV-4, IV-7, IV-11, IV-12, and
IV-16; see Fig 1), and 5 unaffected sons (subjects IV-2,
IV-3, IV-13, IV-14, and IV-15; see Fig 1). These prog-
eny ranged in age from 4 to 25 years. Unaffected sons
and daughters had normal developmental milestones
and normal neurological examinations.
DEVELOPMENTAL MILESTONES. Affected subjects had
normal gestation, labor, and delivery. Delay in achiev-
ing motor milestones was reported for subjects IV-1,
IV-6, IV-9, and IV-17, who were unable to walk in-
dependently until 18 to 24 months of age. All affected
subjects had delayed speech acquisition (range 16 to 36
months of age). Each affected subject had a normal
hearing test. There was no history of psychomotor re-
gression after the onset of seizures.
Seizures were the first evidence of neurological ab-
normality in all affected subjects and began between
four and 14 months of age (average age of seizure onset
was 6.8 months) (Table 1). Descriptions of seizure pat-
tern were consistent with generalized tonic–clonic sei-
zures and drop attacks consisting of brief atonic or
myoclonic seizures with loss of posture. Parents of af-
fected boys did not observe focal neurological signs be-
fore generalized seizures. Seizure frequency was variable
and ranged from 20 seizures per day to several seizures
per month. There were no episodes of status epilepti-
cus. Parents were asked explicitly whether seizure pat-
tern conformed to that of infantile spasms. There was
no description of such seizures in any patient.
Various anticonvulsants had been used as mono-
therapy or in combination (see Table 1). All but one
affected subject experienced reduction in seizure fre-
quency with age; subject IV-5 despite having only two
to three seizures annually as a teenager, experienced
significant increase in his seizure frequency at age 20
years despite compliance with medications. Improved
seizure control was achieved after substituting topira-
mate and lamotrigine for carbamazepine.
At evaluation, 3 subjects (IV-6, age 23 years; IV-8,
age 19 years; IV-9, age 15 years) were seizure free for
10, 2, and 3 years, respectively. Anticonvulsants had
been discontinued for two of these subjects (IV-6 and
IV-8; see Fig 1).
Subject IV-10 developed generalized seizures, similar
to his cousins at the age of 4 months. He died at age 2
years during sleep and his sudden death was attributed
to a seizure. Autopsy report was not available.
MENTAL RETARDATION. For each affected subject,
cognitive impairment was first evident between ages 24
and 36 months. Affected subjects were classified as
Table 1. Clinical Analysis of XMRE Subjects
IV-1 IV-5 IV-6 IV-8 IV-9 IV-10 IV-17 IV-18
Age (yr) 11 23 23 19 15 2 (deceased) 6 3
Age of seizure
onset (mo)
4 10 6 4 6 4 14 6
Type of seizures GTC GTC GTC GTC GTC GTC GTC GTC















3–4/mo 2–5/mo N/A N/A N/A N/A 0–2/mo 0–2/mo
Current anti-
convulsants
CLZ, PHT CLZ, LTG,
TPM
















PB, PHT PB, PHT
XMRE  X-linked mental retardation–epilepsy; CLZ  clonazepam; PHT  phenytoin; VPA  valproate; LTG  lamotrigine; TPM 
topiramate; CBZ  carbamazepine; PB  phenobarbital; FBM  felbamate; GTC  generalized tonic–clonic seizures.
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having trainable mental impairment and required a
special education. Formal assessment with Wechsler
abbreviated scale of intelligence for subject IV-5
showed verbal IQ of 60, performance IQ of 56, and
full-scale IQ of 54; subjects IV-8 scores were 50, 57,
53 and subjectss IV-18 52, 56, and 54, respectively.
Psychological assessment of subject IV-1 at age 8 years
10 months, using the MacArthur Communicative De-
velopment Inventory showed performance at 9- to 16-
month-old levels.13
GENERAL PHYSICAL EXAMINATION. The general physi-
cal examination showed a normal head circumference,
height, and weight (50 to 75% for age) for each sub-
ject, except subject IV-8, who was mildly obese. No
dysmorphic features were noted in any affected subject.
NEUROLOGICAL EXAMINATION. All subjects were able
to perform simple calculations, name common objects
and follow two- or three-step commands. There was no
aphasia or dysarthria. Subject IV-8 had occasional
echolalia. The remainder of the neurological examina-
tion of subjects IV-1, -5, -6, -17, and -18 was notable
only for hyporeflexia in upper and lower extremities.
Although parents described affected children as clumsy,
dysmetria and dysdiadochokinesis were absent. Subject
IV-5, who received clonazepam, topiramate, and lam-
otrigine, had mildly abnormal tandem gait without any
additional abnormalities.
SCOLIOSIS AND GAIT DISTURBANCE WERE PRESENT IN
TWO SUBJECTS. Two affected subjects (IV-8 and IV-9)
had scoliosis, progressive gait disturbance, and bilateral
pes planovalgus. There was no apparent change in in-
tellectual abilities, speech or dexterity of either of these
subjects with progressive gait disturbance. A third af-
fected brother in this sibship (IV-6) had seizures and
MR but did not have scoliosis or gait disturbance. Sco-
liosis in subject IV-9 was managed conservatively, but
his brother (IV-8) benefited from corrective surgery. At
age 8 years, brothers IV-8 and IV-9 developed gait dis-
turbance described as dragging their feet and frequent
falls. Subject IV-8 was still able to walk independently
at age 19 years. His younger brother (IV-9) began to
require a wheelchair at age 10 years. At age 15 years,
he was able to transfer but required support of two
persons to walk. His gait displayed adduction of both
knees and both ankles. Neurological examination of
both brothers demonstrated mild rigidity on lower ex-
tremities without cogwheeling. Deep tendon reflexes
were hypoactive, with the exception of absent Achilles
deep tendon reflexes (both subjects had prominent bi-
lateral pes planovalgus). Plantar response was flexor bi-
laterally. Heel-to-shin testing showed a slight dysme-
tria. Subject IV-9 was treated with oral baclofen
(40 mg/day) and L-dopa (500 mg/day) without
benefit.
Laboratory and Radiological Features
LABORATORY EVALUATIONS. Laboratory evaluations
performed for subjects IV-1, -5, -9, and -17 indicated
no abnormal findings (see Patients and Methods).
ELECTROENCEPHALOGRAPHY. Each affected subject
had at least one EEG. Interictal EEG recordings for
subject IV-1 demonstrated frequent bursts of general-
ized 2-Hz spike and wave and polyspike discharges
with frontocentral amplitude predominance. Photic
stimulation did not provoke EEG changes. Two gen-
eralized tonic–clonic seizures and one myoclonic sei-
zure were recorded during closed-circuit video-EEG
study of subject IV-5. Generalized polyspike and wave
discharges were present before each seizure. Diffuse in-
terictal background slowing and disorganization with
generalized polyspike and slow wave discharges and
multifocal independent sharp wave discharges were also
noted. EEG studies performed at other institutions on
other affected subjects showed only nonspecific gener-
alized slowing.
NEUROIMAGING, ELECTROMYOGRAPHY, AND NERVE CON-
DUCTION STUDIES. MRI of the brain (subjects IV-1,
IV-5, IV-8, IV-9, and IV-17) was normal. EMG and
nerve conduction studies (obtained for subjects IV-5
and IV-9) were normal.
Genetic Linkage Analysis
IDENTIFICATION OF XMRE LOCUS ON XP21.1–P11.4. We
observed linkage of the disorder to a group of micro-
satellite polymorphisms mapped to Xp21.1–p11.4 (Ta-
ble 2). Using the assumption that genetic penetrance
was 0.90, the maximum two-point lod score was
3.83 (  0) for markers DXS8090 (AFM338xa5),
DXS1069 (AFM240wa9), DXS8102 (AFMa062xa9),
and DXS8085 (AFM289wf5). Four additional mark-
ers, DXS1207 (AFM269yc), DXS1069 (AFM240wa9),
DXS8102 (AFMa062xa9), and DXS1056 (AFM-
198vb12) also yielded lod scores of greater than 1.0
(see Table 2). Haplotype analysis (Fig 1) revealed ob-
ligate recombinants (subjects III-5 and III-1; see Fig 1)
for centromeric and telomeric flanking markers
DXS8054 (AFMb291yc9) and DXS1049 (AFM-
155ze1), respectively; separated by 7.7cM.
EXCLUSION OF WEST SYNDROME LOCUS ON XP21.3–P22.1.
A locus for West syndrome has been mapped to
Xp21.3–p22.1 between DXS274 and AHC.10 We
tested linkage of the disorder in our kindred to poly-
morphic microsatellite markers mapped to this locus
and observed significantly negative two-point lod
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scores (DXS1202 [AFM260ye5]–5.55 and DXS7106
[AFM333wf1]–1.89 at   0). These results indicate
that the disorder in our kindred is not linked to the
West syndrome locus on Xp21.3–p22.1 (Fig 2).
EXCLUSION OF TETRASPANIN CODING SEQUENCE MUTA-
TION AS THE CAUSE OF XMRE. We sequenced each of
the seven exons of TM4SF2 and did not identify cod-
ing sequence mutations in affected subjects.
Discussion
We describe an X-linked syndrome of mental retarda-
tion and epilepsy; and report identification of the locus
for this XMRE syndrome on chromosome Xp21.1–
p11.4. We show that this locus is distinct from the
X-linked West syndrome locus by testing genetic link-
age to markers with this locus and observing several
obligate recombinants.
EEG characteristics and degree of MR in our pa-
tients are distinct from males with X-linked West syn-
drome. Seizures in affected subjects in this family were
consistent with symptomatic generalized epilepsy.
None had infantile spasms or hypsarrhythmia, features
that characterize West syndrome.8 West syndrome is
also associated with arrested psychomotor development
after seizure onset, typically resulting in severe mental
retardation. In contrast, our patients did not exhibit
significant regression after the development of epilepsy
and had only mild to moderate mental retardation.
Thirty-one families with nonspecific mental retarda-
tion (MRX 4, 5, 7–15, 17, 18, 20–22, 26, 29, 31, 33,
38, 39, 43–45, and 50–52) have been linked to the
chromosome Xp region that partially or completely
overlaps the XMRE locus we identified.2 It is probable
that a limited number of genes account for mental re-
tardation in these unrelated families. Seizures were a
constant feature in only one of these families, however
(designated MRX38).14 Affected males developed sei-
zures in this family in childhood, but the age of onset
varied significantly (from 2 to 9 years) and epilepsy was
relatively mild; none of these subjects had documented
infantile spasms. Our subjects differ from MRX38 sub-
jects because macrocephaly was a specific distinctive
feature present in every symptomatic MRX38 sub-
Table 2. Two-Point LOD Scores Identify XMRE Locus on Xp21.3–Xp22.1
Marker Penetrance   0.001 0.05 0.10 0.20 0.30 0.40
DXS1214 AFM283wg9 0.9 3.07 0.29 0.32 0.62 0.50 0.22
DXS1049 AFM155ze1 0.9 0.92 0.57 0.68 0.60 0.38 0.15
DXS8090 AFM338xa5 0.9 3.83 3.50 3.16 2.41 1.58 0.68
DXS1069 AFM240wa9 0.9 3.83 3.50 3.16 2.41 1.58 0.68
DXS8102 AFMa062xa9 0.9 1.47 1.32 1.17 0.84 0.50 0.18
DXS1056 AFM198vb12 0.9 0.92 2.24 2.22 1.84 1.26 0.57
DXS8012 AFMa124xd9 0.9 3.83 3.50 3.16 2.41 1.58 0.68
DXS1207 AFM269yc5 0.9 2.11 1.96 1.78 1.42 0.99 0.48
DXS8085 AFM289wf5 0.9 3.83 3.50 3.16 2.41 1.58 0.68
DXS8054 AFMb291yc9 0.9 1.17 0.07 0.24 0.27 0.18 0.06
XMRE  X-linked mental retardation–epilepsy.
Fig 2. Schematic representation of the X-linked mental retar-
dation–epilepsy (XMRE) and West syndrome loci.
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ject.14 We did not observe head circumference above
the 98% in any affected subjects from the XMRE fam-
ily presented in this study. Absence of macrocephaly,
more severe epilepsy, and earlier age of seizure onset
suggest that XMRE is distinct from other types of non-
specific X-linked mental retardation linked to Xp re-
gion.
Eight genes that cause nonspecific mental retarda-
tion have been identified, one of which, tetraspanin
(TM4SF2), was mapped to the XMRE locus.11,15 The
TM4SF2 gene was identified by positional cloning in a
mentally retarded female patient who had an X;2 bal-
anced translocation. TM4SF2 was interrupted by this
translocation. Subsequently, TM4SF2 coding sequence
point mutations were found in 2 small families with
nonspecific mental retardation. Even though none of
the patients with identified TM4SF2 mutations had
seizures, this gene was an important candidate gene for
XMRE. Nonetheless, sequencing the TM4SF2 coding
region did not identify any coding sequence mutations
in XMRE subjects. We cannot exclude, however, the
possibility that disturbance in transcriptional regulation
or mRNA splicing of this gene could underlie XMRE.
Identified genes causing XLMR are a heterogeneous
group, but most of these genes are involved in signal-
ing pathways.15 Several genes implicated in XLMR be-
long to the family of guanine nucleotide exchange fac-
tors for Rho GTPase, with putative roles in regulation
of neuronal plasticity and cytoskeletal organization.16
Other XLMR genes, including TM4SF2, are trans-
membrane proteins that interact with extracellular mol-
ecules and participate in signaling pathways.11 Another
recognized cause of seizures and MR are abnormalities
in neuronal migration.17 Even though neuroimaging
did not indicate any obvious migration defects, genes
controlling neuronal migration remain important can-
didate genes as a cause of XMRE. Given the size
(7.7cM) of the XMRE locus, identifying the XMRE
gene may require ascertaining additional XMRE kin-
dreds and reduction of the locus. Discovering the
XMRE gene will advance our knowledge of the causes
and, ultimately, treatment for MR and epilepsy.
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